Shoichi Deguchi

Shoichi Deguchi

Auto-generated profile, based on publicly available information

Shoichi Deguchi

Department of Neurosurgery, Nagoya University School of Medicine , Nagoya

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SDShoichi Deguchi
Shoichi Deguchi
TOTakuma Oishi
Takuma Oishi
KMKoichi Mitsuya
Koichi Mitsuya
YKYuko Kakuda
Yuko Kakuda
MEMasahiro Endo
Masahiro Endo
NHNakamasa Hayashi
Nakamasa Hayashi
T2-FLAIR mismatch sign is known as a highly specific imaging marker of IDH-mutant astrocytomas. This study was intended to clarify what the T2-FLAIR mismatch sign represents by pathological analysis of lower-grade gliomas rediagnosed in accordance with the WHO 2016 classification. We retrospectively analyzed the records of 64 patients diagnosed with WHO grade II and III diffuse gliomas between June 2009 and November 2018. T2-FLAIR mismatch sign was found in 10 (45%) out of 22 patients with IDH-mutant astrocytoma, 1 (5%) out of 20 with oligodendroglioma, and 1 (5%) out of 22 with IDH-wild-type astrocytoma. T2-FLAIR mismatch sign as a marker of IDH-mutant astrocytomas showed positive predictive value of 83%. Among 22 patients with IDH-mutant astrocytomas, microcystic change was found in eight, of which seven showed T2-FLAIR mismatch sign. Microcystic change was significantly associated with T2-FLAIR mismatch sign (P < 0.01). From multi-sampling in a patient, abundant microcysts were observed upon HE staining of specimens from the T2-FLAIR mismatched region, while microcysts were hardly observed from the T2-FLAIR matched one. All three protoplasmic astrocytomas among our IDH-mutant astrocytomas presented T2-FLAIR mismatch sign. In conclusion, T2-FLAIR mismatch sign may reflect microcyst formation in IDH-mutant astrocytomas and be common in IDH-mutant protoplasmic astrocytoma.

1 January 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
YNYoko Nakasu
Yoko Nakasu
SDShoichi Deguchi
Shoichi Deguchi
SNSatoshi Nakasu
Satoshi Nakasu
MYMutsumi Yamazaki
Mutsumi Yamazaki
ANAkifumi Notsu
Akifumi Notsu
NHNakamasa Hayashi
Nakamasa Hayashi
Background: Cerebrospinal fluid (CSF) cytology remains the gold standard approach for diagnosing of leptomeningeal metastases (LM), but has clinical problems due to its low sensitivity. This systemic review and meta-analysis evaluated the diagnostic accuracy of the novel CSF biomarkers of liquid biopsy and magnetic resonance imaging (MRI) for detecting LM in patients with solid cancers.Methods: A systematic search of electronic databases was conducted to identify all published diagnostic accuracy studies on CSF liquid biopsies and MRI since January 2000 with registration for PROSPERO (#CRD42022301988). Articles were selected based on pre-defined inclusion and exclusion criteria following the PRISMA 2020 statement.Results: The search yielded 3790 citations, and 10 studies with 668 patients were included in the final analysis. The pooled prevalence of LM was 50.9% (340/668). The respective sensitivity and specificity for index tests were as follows: circulating tumor cells (CTC), 87.0% (95% confidence interval [CI] 77.9–92.6%) and 93.8% (86.9–97.2%); cell-free tumor DNA, 97.9% (19.3–100%) and 89.0% (25.3–99.5%); MRI 59.4% (60.7–76.9%) and 97.6% (77.3–99.8%); cytology, 71.9% (54.7–82.9%) and 100%. The diagnostic odds ratio was 100.6 (29.38–344.09) for CTC and 93.3 (88.42–1034.05) for MRI.Conclusion: Novel CSF liquid biopsies and MRI may offer improved diagnostic accuracy for LM from solid cancers; however, further research is required to specify the threshold values and to construct standards for individual primary cancers.

8 May 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JWJunichiro Watanabe
Junichiro Watanabe
KMKoichi Mitsuya
Koichi Mitsuya
SNShogo Nakamoto
Shogo Nakamoto
HHHideyuki Harada
Hideyuki Harada
SDShoichi Deguchi
Shoichi Deguchi
YNYoko Nakasu
Yoko Nakasu

9 July 2020 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SDShoichi Deguchi
Shoichi Deguchi
YNYoko Nakasu
Yoko Nakasu
TSTsukasa Sakaida
Tsukasa Sakaida
JAJiro Akimoto
Jiro Akimoto
KTKuniaki Tanahashi
Kuniaki Tanahashi
YNYoshitaka Narita
Yoshitaka Narita

1 November 2019 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
SDShoichi Deguchi
Shoichi Deguchi
KNKazuaki Nakashima
Kazuaki Nakashima
KMKoji Muramatsu
Koji Muramatsu
KMKoichi Mitsuya
Koichi Mitsuya
TOTakuma Oishi
Takuma Oishi
YNYoko Nakasu
Yoko Nakasu

1 January 2024 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
MKMasayuki Kanamori
Masayuki Kanamori
STShunsuke Tsuzuki
Shunsuke Tsuzuki
ISIchiyo Shibahara
Ichiyo Shibahara
KSKuniaki Saito
Kuniaki Saito
YSYoshiteru Shimoda
Yoshiteru Shimoda
YNYOSHITAKA NARITA
YOSHITAKA NARITA
Background: The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods: This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results: Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions: TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.